ProMetic Life Sciences Inc. (TSE:PLI) has received an average rating of “Buy” from the eight research firms that are covering the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is C$4.86.

A number of research firms recently commented on PLI. Scotiabank reiterated an “outperform” rating and set a C$5.00 price target on shares of ProMetic Life Sciences in a report on Tuesday, August 16th. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a report on Wednesday, June 15th. TD Securities reiterated a “speculative buy” rating and set a C$4.50 price target on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Finally, CIBC reduced their price target on ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th.

Shares of ProMetic Life Sciences (TSE:PLI) traded down 2.84% during trading on Thursday, hitting $3.08. The stock had a trading volume of 933,368 shares. The stock’s 50-day moving average is $2.92 and its 200-day moving average is $3.01. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62. The stock’s market capitalization is $1.86 billion.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.